Samuel E. Lynch, President & CEO of BioMimetic Therapeutics,
Rings The NASDAQ Stock Market Closing Bell

Wednesday, May 31, 2006
at NASDAQ's MarketSite
in New York City.

BioMimetic Therapeutics [BMTI]

Samuel E. Lynch, President & CEO of BioMimetic Therapeutics (Nasdaq: BMTI) presides over the closing bell to celebrate its initial public offering on the NASDAQ.

BioMimetic Therapeutics, Inc. develops and commercializes bio-active drug-device combination products for the healing of musculoskeletal injuries and diseases, including periodontal, orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA in November 2005 for its first product GEM 21S(R) as a grafting material for bone and periodontal regeneration. A pivotal human clinical trial demonstrated the safety and efficacy of its platform technology in this indication, resulting in significantly faster healing and improved bone healing on clinical X-rays. The Company's product and product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration. The Company believes its regenerative therapies will improve the treatment options and quality of life for millions of patients with injuries or deterioration of bones, cartilage, tendons or ligaments. For further information, visit http://www.biomimetics.com

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 5/31/2006 Download Hi-Res Quality Photo of this NASDAQ Market Close - Pictured: Samuel E. Lynch, President & CEO of BioMimetic Therapeutics, rings the Closing Bell These photos are Copyright 2006, The Nasdaq Stock Market Inc. and available for re-publication by the news media only. Any commercial use is strictly prohibited without the prior written consent of The Nasdaq Stock Market Inc. © Copyright 2006, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.